Stocks and Investing Stocks and Investing
Mon, April 3, 2023

Brian Cheng Maintained (BCAB) at Buy with Decreased Target to $19 on, Apr 3rd, 2023


Published on 2024-10-28 02:32:39 - WOPRAI, Brian Cheng
  Print publication without navigation


Brian Cheng of JP Morgan, Maintained "BioAtla, Inc." (BCAB) at Buy with Decreased Target from $23 to $19 on, Apr 3rd, 2023.

Brian has made no other calls on BCAB in the last 4 months.



There are 5 other peers that have a rating on BCAB. Out of the 5 peers that are also analyzing BCAB, 1 agrees with Brian's Rating of Hold. Following is the relevant analyst calls for the last 4 months


  • Tiago Fauth of "Credit Suisse" Reiterated at Hold and Held Target at $8 on, Friday, March 24th, 2023


These are the ratings of the 4 analyists that currently disagree with Brian


  • Thomas Shrader of "BTIG" Maintained at Strong Buy with Decreased Target to $13 on, Tuesday, March 28th, 2023
  • Reni Benjamin of "JMP Securities" Maintained at Buy with Decreased Target to $12 on, Monday, March 27th, 2023
  • Arthur He of "HC Wainwright & Co." Maintained at Strong Buy with Decreased Target to $17 on, Friday, March 24th, 2023
  • Tony Butler of "EF Hutton" Reiterated at Strong Buy and Held Target at $25 on, Friday, March 24th, 2023
Contributing Sources